Pnds Medical secures £192k for biotechnology research

Experimental development in bioinformatics and DNA/RNA research is the primary focus of Pnds Medical Ltd, a London-based biotechnology firm. The company recently secured an estimated £192k in new funding, resulting in an estimated post-money valuation of £2.7m.

This latest injection follows a £62.6k round in February 2026 which valued the business at £2.9m. In December 2025, the company raised £345.6k at a £2.8m valuation. These figures contrast with a peak valuation of £5.5m reached in January 2025 following a £163k investment. Earlier in 2024, the business raised £230.9k in August and £133.3k in June at valuations of £5.4m and £5.1m respectively.

Founded in 2023, the startup also works on proteins, molecules, cell and tissue culture, and nanobiotechnology. Accounts for the year ended 31 August 2025 show the company employed two people. During its first year of operation, Pnds Medical completed three separate funding rounds in October 2023 totaling £150.7k at valuations ranging between £212.6k and £312.8k.